Santhera Reports Solid Top-line Growth in 2017 and Reiterates its Strategy to Obtain Approval for Idebenone in Duchenne Muscular Dystrophy

Tuesday, March 20, 2018 @ 12:00 am

Pratteln, Switzerland, March 20, 2018 - Santhera Pharmaceuticals (SIX: SANN) reports the Group's audited financial results for 2017. Net revenues from sales of lead product Raxone® (idebenone) increased by 21% compared to the previous year to CHF 22.9 million. The operating result of CHF -50.5 million reflects predominantly investments in several ongoing clinical development programs and preparations for regulatory submissions as well as commercial activities in Europe and the US. The net result amounted to CHF -51.5 million (2016: CHF -35.4 million), in line with the Company's guidance. With the in-licensing of a clinical stage drug candidate in February 2018, Santhera achieved the key objective of broadening its pipeline in rare diseases. Santhera will continue to review opportunities to expand its product pipeline for the treatment of rare neuro-ophthalmological, neuromuscular and pulmonary diseases. At the end of February 2018, the Company had cash, cash equivalents and short-term financial assets of CHF 50.9 million, allowing it to pursue its planned development and commercial activities.

Download the the full media release below.

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

SOTIO enters into agreement with Biocytogen to expand antibody-drug conjugates pipeline

Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite platform Agreement will enable SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCs Biocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 million
July 16, 2024

Asceneuron secures USD 100 million financing to advance therapeutics in neurodegenerative diseases

Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical developme
July 16, 2024

LimmaTech appoints Staph Leavenworth Bakali as Chairman of the Board

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced the appointment of Staph Leavenworth Bakali as independent Chairman of its Board of Directors. Mr. Leavenworth Bakali brings over 30 years of senior executive and board-level experience in the life science and healthcare industries.
July 1, 2024

Newron flash update “A pivotal year” - potential of schizophrenia drug

June 27, 2024

Ymmunobio and EVIIVE: Collaboration to develop advanced liquid biopsy for cancer patients

Ymmunobio and EVIIVE are pleased to announce their strategic collaboration to develop an innovative liquid biopsy technology utilizing extracellular vesicles (EVs). This partnership marks a significant advancement in precision medicine, aiming to enhance disease detection and patient monitoring accuracy and efficacy.
June 24, 2024